Overview

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Status:
Active, not recruiting

Trial end date:
2022-07-26

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether denosumab compared to placebo, will reduce the rate of first clinical fracture in women with non-metastatic breast cancer receiving (non-steroidal) aromatase inhibitor therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Collaborator:

Austrian Breast and Colorectal Cancer Study Group

Treatments:

Aromatase Inhibitors
Denosumab
Zoledronic Acid